Tumor Microenvironment

University Hospital Heidelberg

Status: Active, not recruiting

Conditions: Lung Adenocarcinoma

Study type: Observational

Funder types: Other

Identifiers

NCT05982574

S-515/2013 S-270/2001

Details and patient eligibility

About

Cancer immunotherapy has the great potential to achieve long-term survival in patients with a solid malignancy. However, the beneficial effect of cancer immunotherapy is seen in only a minority of patients. Mounting evidence suggests that immunosuppressive features in the tumor microenvironment prevent an effective antitumor defense. The aim of the investigators is to comprehensively analyze the cytokine profile and the tumor immune infiltrate in the tumor microenvironment and to investigate its prognostic significance in patients with radically resected lung adenocarcinoma.

Enrollment: 300 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Lung adenocarcinoma
• Tumor stage IB and II
• With or without adjuvant therapy
• Complete surgical resection (R0)
• No distant metastasis at the time of surgery (M0)

Exclusion criteria

• Second cancer within 5 years